Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials-Reference-Cited by-同舟云学术

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

Published:2022-08 Issue:10351 Volume:400 Page:512-521
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Chihara Dai,Lin Ruitao,Flowers Christopher R,Finnigan Shanda R,Cordes Lisa M,Fukuda Yoko,Huang Erich P,Rubinstein Larry V,Nastoupil Loretta J,Ivy S Percy,Doroshow James H,Takebe Naoko

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Risks and benefits of phase 1 oncology trials, 1991 through 2002;Horstmann;N Engl J Med,2005

2. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials;Roberts;JAMA,2004

3. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics;Von Hoff;Invest New Drugs,1991

4. Responses and toxic deaths in phase I clinical trials;Decoster;Ann Oncol,1990

5. Therapeutic response in phase I trials of antineoplastic agents;Estey;Cancer Treat Rep,1986

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer;Oral Oncology Reports;2024-09

2. Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels;Entropy;2024-08-14

3. Beginning at the End? Rethinking the Timing of Enrollment Into Early Phase Clinical Trials;JCO Oncology Practice;2024-07-30

4. Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials;JAMA Network Open;2024-07-11

5. Optimizing care in early phase cancer trials: The role of palliative care;Cancer Treatment Reviews;2024-07